DeutschNewstral
Article
jdsupra.com on 2019-08-28 16:22
Attention Pharma Industry: Update your Drug Product Listings Now (FDA Will Begin to Deactivate Old and Outdated Listings Soon)
Related news
- FDA Guidance on DSCSA Product Identifier Requirementsjdsupra.com
- FDA proposes streamlining combination product regulationsjdsupra.com
- FDA Finalizes New Definition of Biological Productjdsupra.com
- FDA, FTC Warn CBD Maker Over Product Claimsjdsupra.com
- Curaleaf Responds to FDA Warning Over CBD Product Marketingjdsupra.com
- FDA Will Facilitate Biological Product Development Against COVID-19jdsupra.com
- Pharma Supply Chain Cornucopia: More FDA Guidance on DSCSA Product Identifier and Verification Requirementsjdsupra.com
- FDA fails to police its elite MD-advisers’ ‘pay later’ deals with Big Pharmajdsupra.com
- FDA issues guidance for industry on wholesale distributor verification requirement for saleable returned drug productjdsupra.com
- FDA Issues Two Product-Specific Guidances for Chloroquine Phosphate and Hydroxychloroquine Sulfate Drug Developersjdsupra.com
- Consumer Product Regulatory Priorities in 2019: An Ever-Shifting Landscape for FDAjdsupra.com
- CBD Product Sellers Beware: FDA Issued Warning Letters Claiming Certain CBD Products Are Unapproved New Human And Animal Drugsjdsupra.com
- FDA Issues Final Guidance on “Considerations in Demonstrating Interchangeability With a Reference Product”jdsupra.com
- Not So Clean After All: FDA Takes Aim at Manufacturer of OTC Hand Sanitizer Product Line Making Disease Prevention Claims from Ebola to the Flujdsupra.com
- And Now For Something Completely Different: FDA Actions to Alleviate Regulatory Burdens For Product Sponsors During the COVID-19 Pandemicjdsupra.com
- NIST to Withdraw Outdated Cybersecurity Publicationsjdsupra.com
- Pharma Review - Issue 3jdsupra.com
- More Product Labeling Woesjdsupra.com
- Unbelievable Product Liability Lawsuitsjdsupra.com
- Opioids Have Our Attentionjdsupra.com